Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Our results provided direct evidence for a novel, PPARα-mediated mechanism responsible for the beneficial effects of RSV on hepatic steatosis. 31173696 2020
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE PPARα contributes to the CYP2A5 protective effects on fatty liver but it opposes to the protective effects on obesity. 29568101 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 PosttranslationalModification disease BEFREE Paternal hyperglycemia induces transgenerational inheritance of susceptibility to hepatic steatosis in rats involving altered methylation on Pparα promoter. 30404040 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Elevated lipolysis in adipose tissue by doxorubicin via PPARα activation associated with hepatic steatosis and insulin resistance. 30452912 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Some of the natural AR inhibitors have been reported to attenuate hepatic steatosis through the regulation of PPARα-mediated fatty acid oxidation. 31589122 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE During the development of hepatic steatosis (8-16 weeks), PPARα was activated as indicated by its target genes as well as the elevated peroxisomal acyl-CoA oxidase activity. 30120929 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 AlteredExpression disease BEFREE Aged and Zmpste24-deficient livers share several features, including nuclear lamina abnormalities, increased Foxa2 binding, de-repression of PPAR- and LXR-dependent gene expression, and fatty liver. 29484800 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 AlteredExpression disease BEFREE IRD induced liver steatosis and oxidative stress (higher levels of protein oxidation and lipid peroxidation with glutathione depletion), mitochondrial dysfunction (decreased citrate synthase and complex I and II activities) and loss of polyunsaturated fatty acids (PUFAs), with a drastic enhancement in the sterol regulatory element-binding protein-1c (SREBP-1c)/peroxisome proliferator-activated receptor-α (PPAR-α) ratio upregulating the expression of lipogenic enzymes (acetyl-CoA carboxylase, fatty acid (FA) synthase and stearoyl desaturase 2) and downregulating those involved in FA oxidation (carnitine palmitoyl transferase and acyl-CoA oxidase) over values in the CD group. 30153476 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Ameliorative effect of Sedum sarmentosum Bunge extract on Tilapia fatty liver via the PPAR and P53 signaling pathway. 29855491 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 AlteredExpression disease BEFREE In this study, we showed that the overexpression of PIK3R3 promoted hepatic fatty acid oxidation via PIK3R3-induced expression of PPARα, thus improving the fatty liver phenotype in high-fat diet (HFD)-induced mice. 29350678 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 AlteredExpression disease BEFREE Furthermore, MG clearly alleviated serum TG and total cholesterol release; upregulated AKT, AMPK, and PPARα expression; suppressed SREBP-1c generation; and alleviated hepatic steatosis and dyslipidemia in Ty-induced hyperlipidemia mice. 29467759 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Nuciferine improved lipid profile and attenuated hepatic steatosis in HFD/STZ-induced diabetic mice by activating the PPARα/PGC1α pathway. 30129056 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Therefore, fatty liver in PUFA deficiency is attributable to suppression of the FA-degrading system probably from decreased PPARα adaptive responsiveness, and PUFA may be an essential factor for PPARα functioning. 28724855 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Supplementation with Docosahexaenoic Acid and Extra Virgin Olive Oil Prevents Liver Steatosis Induced by a High-Fat Diet in Mice through PPAR-α and Nrf2 Upregulation with Concomitant SREBP-1c and NF-kB Downregulation. 28940752 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging. 28545035 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRα and PPARα dysregulation: implications for HIV-specific pathogenesis of NAFLD. 29042644 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 AlteredExpression disease BEFREE Hepatic miR-141 and miR-200c RNA levels were highly induced in human patients with NASH fatty liver and in WT MCD mice. miR-141/200c-/- MCD mice had reduced liver weights and triglyceride (TG) levels, which was associated with increased microsomal TG transfer protein (MTTP) and PPARα but reduced SREBP1c and FAS expression. 29093267 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 AlteredExpression disease BEFREE Liver steatosis was reduced by RBEE supplementation of LFD (1% RBEE) and HFD (1 and 5% RBEE) and nuclear peroxisome proliferator-activated receptor-α expression upregulated in the HDF 5% RBEE group. 28359358 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE The HC diet also up-regulated the expression of the transcription factor peroxisome proliferator-activated receptor α (PPARα) and its downstream targets involved in fatty acid oxidation, including carnitine palmitoyltransferase-1,2 (CPT-1, CPT-2), liver-fatty acid-binding protein (L-FABP), and acyl-CoA oxidase (ACO). 28287130 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Recombinant PEDF and PPARα agonist diminished the TNFα-induced hepatic steatosis. 28111231 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes. 25605057 2015
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE APS treatment suppressed abnormal glycolipid metabolism and insulin resistance following 8 weeks of catch‑up growth by improving hepatic SIRT1‑PPARα‑FGF21 intracellular signaling and reducing chronic inflammation, and by partially attenuating hepatic steatosis. 26323321 2015
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE The feed-back loop between miR-17-5p and PPAR-α played a key role in the induction of steatosis and fatty liver development. 25896250 2015
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 AlteredExpression disease BEFREE Forced FGF21 expression in partial hepatectomized hPPARα(PAC) reduced hepatic steatosis, prevented focal necrosis, and restored liver mass. 25991671 2015
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.600 Biomarker disease BEFREE Clinical studies have reported that PPARα activation does not improve hepatic steatosis. 24926685 2014